CN107119076A - 一种免疫缺陷小鼠模型、其制备方法及应用 - Google Patents
一种免疫缺陷小鼠模型、其制备方法及应用 Download PDFInfo
- Publication number
- CN107119076A CN107119076A CN201610103735.6A CN201610103735A CN107119076A CN 107119076 A CN107119076 A CN 107119076A CN 201610103735 A CN201610103735 A CN 201610103735A CN 107119076 A CN107119076 A CN 107119076A
- Authority
- CN
- China
- Prior art keywords
- mouse
- nsi
- genes
- talen
- nsif
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011575 immunodeficient mouse model Methods 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 220
- 241000699670 Mus sp. Species 0.000 claims abstract description 39
- 101150094145 FAH gene Proteins 0.000 claims abstract description 37
- 101100334119 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) fahA gene Proteins 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 238000010172 mouse model Methods 0.000 claims abstract description 15
- 108700022368 Whn Proteins 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 230000002950 deficient Effects 0.000 claims abstract description 8
- 238000010459 TALEN Methods 0.000 claims description 57
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 49
- 210000004185 liver Anatomy 0.000 claims description 43
- 235000013601 eggs Nutrition 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 238000000338 in vitro Methods 0.000 claims description 25
- 238000013518 transcription Methods 0.000 claims description 25
- 230000035897 transcription Effects 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 238000003209 gene knockout Methods 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 17
- 108020005004 Guide RNA Proteins 0.000 claims description 16
- 210000001161 mammalian embryo Anatomy 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 15
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 11
- 239000007995 HEPES buffer Substances 0.000 claims description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 11
- 230000006651 lactation Effects 0.000 claims description 9
- 210000004291 uterus Anatomy 0.000 claims description 9
- 101150083447 Foxn1 gene Proteins 0.000 claims description 8
- 101100067103 Mus musculus Foxn1 gene Proteins 0.000 claims description 8
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 238000011789 NOD SCID mouse Methods 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 108091092584 GDNA Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000012239 gene modification Methods 0.000 claims description 4
- 230000005017 genetic modification Effects 0.000 claims description 4
- 235000013617 genetically modified food Nutrition 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000003252 repetitive effect Effects 0.000 claims description 4
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000007547 defect Effects 0.000 abstract description 10
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 230000003910 liver physiology Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- 210000005229 liver cell Anatomy 0.000 description 16
- 238000011740 C57BL/6 mouse Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 229960001721 nitisinone Drugs 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000011577 humanized mouse model Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 229940076788 pyruvate Drugs 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 206010019663 Hepatic failure Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 108010065394 aminopherase Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 231100000835 liver failure Toxicity 0.000 description 4
- 208000007903 liver failure Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 3
- 101710124239 Poly(A) polymerase Proteins 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 244000144987 brood Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100191385 Mus musculus Prkdc gene Proteins 0.000 description 1
- 101000652434 Mus musculus Protein SON Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 101150017145 nod gene Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610103735.6A CN107119076A (zh) | 2016-02-25 | 2016-02-25 | 一种免疫缺陷小鼠模型、其制备方法及应用 |
PCT/CN2017/071697 WO2017143894A1 (zh) | 2016-02-25 | 2017-01-19 | 免疫缺陷小鼠、其制备方法及应用 |
CN201780000020.0A CN106661593A (zh) | 2016-02-25 | 2017-01-19 | 一种免疫缺陷小鼠、其制备方法及应用 |
CN201911347317.1A CN110951787B (zh) | 2016-02-25 | 2017-01-19 | 一种免疫缺陷小鼠、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610103735.6A CN107119076A (zh) | 2016-02-25 | 2016-02-25 | 一种免疫缺陷小鼠模型、其制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107119076A true CN107119076A (zh) | 2017-09-01 |
Family
ID=59684708
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610103735.6A Pending CN107119076A (zh) | 2016-02-25 | 2016-02-25 | 一种免疫缺陷小鼠模型、其制备方法及应用 |
CN201911347317.1A Active CN110951787B (zh) | 2016-02-25 | 2017-01-19 | 一种免疫缺陷小鼠、其制备方法及应用 |
CN201780000020.0A Pending CN106661593A (zh) | 2016-02-25 | 2017-01-19 | 一种免疫缺陷小鼠、其制备方法及应用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911347317.1A Active CN110951787B (zh) | 2016-02-25 | 2017-01-19 | 一种免疫缺陷小鼠、其制备方法及应用 |
CN201780000020.0A Pending CN106661593A (zh) | 2016-02-25 | 2017-01-19 | 一种免疫缺陷小鼠、其制备方法及应用 |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN107119076A (zh) |
WO (1) | WO2017143894A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108504685A (zh) * | 2018-03-27 | 2018-09-07 | 宜明细胞生物科技有限公司 | 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法 |
CN108504624A (zh) * | 2018-04-08 | 2018-09-07 | 深圳市体内生物医药科技有限公司 | 一种免疫缺陷小鼠模型的新应用 |
CN108925500A (zh) * | 2018-05-25 | 2018-12-04 | 广东药科大学 | Lfa-1敲除的自发肠道肿瘤基因工程鼠的应用与研究方法 |
CN109735485A (zh) * | 2019-01-29 | 2019-05-10 | 深圳市拓普生物科技有限公司 | 人源化肝脏动物模型及其构建方法和应用 |
WO2023077360A1 (zh) * | 2021-11-04 | 2023-05-11 | 云南农业大学 | 一种构建重症免疫缺陷和肝损伤双重猪模型的方法及应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108396036B (zh) * | 2018-03-01 | 2021-08-03 | 昆明医科大学 | 一种过表达cox5a转基因鼠模型及其构建方法与应用 |
WO2019179439A1 (en) * | 2018-03-19 | 2019-09-26 | Beijing Biocytogen Co., Ltd | Foxn1 knockout non-human animal |
CN111100876A (zh) * | 2018-10-25 | 2020-05-05 | 立沃生物科技(深圳)有限公司 | CRISPR-Cas9特异性敲除FAH基因的方法及特异性sgRNA |
US11926817B2 (en) | 2019-08-09 | 2024-03-12 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
CN111621523A (zh) * | 2020-06-09 | 2020-09-04 | 湖南昭泰生物医药有限公司 | 一种ace2细胞人源化的小鼠模型及其构建方法和应用 |
CN113930446A (zh) * | 2020-07-13 | 2022-01-14 | 黄菁 | 对非人动物基因改造的方法及构建的免疫缺陷动物模型 |
CN112522202B (zh) * | 2020-09-23 | 2022-04-05 | 南京启真基因工程有限公司 | 制备addi四个基因联合敲除的重症免疫缺陷猪源重组细胞的方法及其专用试剂盒 |
CN112237637A (zh) * | 2020-10-10 | 2021-01-19 | 广州市天河诺亚生物工程有限公司 | 一种基于免疫缺陷小鼠脑瘫模型的细胞治疗研究方法 |
CN112243949A (zh) * | 2020-11-09 | 2021-01-22 | 广州市天河诺亚生物工程有限公司 | 一种脑瘫小鼠动物模型的构建及评价方法 |
CN114763557A (zh) * | 2021-01-13 | 2022-07-19 | 北京市农林科学院 | Ddx5在抗病毒和调节免疫反应中的应用 |
CN113106101B (zh) * | 2021-05-11 | 2023-04-07 | 广州欣意生物技术有限公司 | 一种nod遗传背景双基因缺陷小鼠模型的制备方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102460162A (zh) * | 2009-05-01 | 2012-05-16 | 俄勒冈健康科学大学 | 体内扩增人肝细胞的方法 |
CN103409468B (zh) * | 2013-03-20 | 2015-08-12 | 中国科学院广州生物医药与健康研究院 | 一种免疫缺陷小鼠模型的建立方法 |
WO2015086727A2 (en) * | 2013-12-11 | 2015-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method for patients suffering of a cancer |
-
2016
- 2016-02-25 CN CN201610103735.6A patent/CN107119076A/zh active Pending
-
2017
- 2017-01-19 CN CN201911347317.1A patent/CN110951787B/zh active Active
- 2017-01-19 CN CN201780000020.0A patent/CN106661593A/zh active Pending
- 2017-01-19 WO PCT/CN2017/071697 patent/WO2017143894A1/zh active Application Filing
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108504685A (zh) * | 2018-03-27 | 2018-09-07 | 宜明细胞生物科技有限公司 | 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法 |
CN108504624A (zh) * | 2018-04-08 | 2018-09-07 | 深圳市体内生物医药科技有限公司 | 一种免疫缺陷小鼠模型的新应用 |
CN108925500A (zh) * | 2018-05-25 | 2018-12-04 | 广东药科大学 | Lfa-1敲除的自发肠道肿瘤基因工程鼠的应用与研究方法 |
CN109735485A (zh) * | 2019-01-29 | 2019-05-10 | 深圳市拓普生物科技有限公司 | 人源化肝脏动物模型及其构建方法和应用 |
CN109735485B (zh) * | 2019-01-29 | 2021-04-16 | 深圳市拓普生物科技有限公司 | 人源化肝脏动物模型及其构建方法和应用 |
WO2023077360A1 (zh) * | 2021-11-04 | 2023-05-11 | 云南农业大学 | 一种构建重症免疫缺陷和肝损伤双重猪模型的方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2017143894A1 (zh) | 2017-08-31 |
CN106661593A (zh) | 2017-05-10 |
CN110951787B (zh) | 2023-08-08 |
CN110951787A (zh) | 2020-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107119076A (zh) | 一种免疫缺陷小鼠模型、其制备方法及应用 | |
Yao et al. | Tild-CRISPR allows for efficient and precise gene knockin in mouse and human cells | |
CN108660161B (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
CN107287245B (zh) | 一种基于CRISPR/Cas9技术的Glrx1基因敲除动物模型的构建方法 | |
CN106047930B (zh) | 一种PS1基因条件性敲除flox大鼠的制备方法 | |
CN103930550B (zh) | 经遗传修饰的动物及其生成方法 | |
US20160208214A1 (en) | Methods and compositions for generation of developmentally-incompetent eggs in recipients of nuclear genetic transfer | |
Sato et al. | Recent advances and future perspectives of in vivo targeted delivery of genome-editing reagents to germ cells, embryos, and fetuses in mice | |
JP6958917B2 (ja) | 遺伝子ノックイン細胞の作製方法 | |
CN106282231B (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
CN105505879B (zh) | 一种培养转基因动物胚胎细胞或转基因动物的方法及培养基 | |
CN113088521A (zh) | 一种基于CRISPR/Cas9技术的Ahnak2基因敲除动物模型的构建方法 | |
KR20160012735A (ko) | Dyrk1aa 유전자가 결실된 제브라피쉬 모델 및 이를 이용한 혈관 발생 결함 예방 및 치료제 스크리닝 방법 | |
CN110484549A (zh) | 基因组靶向修饰方法 | |
Sato et al. | Sequential i-GONAD: An improved in vivo technique for CRISPR/Cas9-based genetic manipulations in mice | |
CN110184301A (zh) | 通过Tild-CRISPR实现高效精确的靶向整合 | |
Kang et al. | Apancreatic pigs cloned using Pdx1-disrupted fibroblasts created via TALEN-mediated mutagenesis | |
CN113234756A (zh) | 一种基于CRISPR/Cas9技术的LAMA3基因敲除动物模型的构建方法 | |
CN110250108B (zh) | Rprm基因敲除小鼠模型及其构建方法与应用 | |
US20200149063A1 (en) | Methods for gender determination and selection of avian embryos in unhatched eggs | |
CN114592075B (zh) | 一种黄鳝生殖细胞异种移植及移植后嵌合性腺的检测方法 | |
CN110283851B (zh) | 与恶性胸腔积液相关的靶点myo9b及其应用 | |
CN101412999A (zh) | 一种基因打靶定点转基因方法及其应用 | |
CN104087615B (zh) | 一种血管瘤动物模型的建系方法 | |
Tesson et al. | Genome editing in rats using TALE nucleases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190318 Address after: 410007 402 houses of Zhongnan headquarters base 688, two, 688 Wan Li South Road, Yuhua District, Changsha, Hunan Applicant after: Hunan Zhao Tai Biological Medicine Co., Ltd. Address before: 518100 5th Floor, Five Buildings, Hongwan Industrial Zone, Gushi Community, Xixiang Street, Baoan District, Shenzhen City, Guangdong Province Applicant before: Shenzhen in vivo biological medicine technology Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170901 |
|
WD01 | Invention patent application deemed withdrawn after publication |